comparemela.com

Page 24 - Mary Coleman News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BioXcel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides

Press release content from Globe Newswire. The AP news staff was not involved in its creation. BioXcel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides . BioXcel TherapeuticsMarch 11, 2021 GMT New Drug Application (“NDA”) submitted to the U.S. Food and Drug Administration (“FDA”) for BXCL501 for the acute treatment of schizophrenia and bipolar disorder related agitation TRANQUILITY achieved primary and secondary endpoints with both doses of BXCL501; End of Phase 2 meeting with the FDA planned for Q2 2021 RELEASE trial on track to report topline results in Q1 2021 Topline results from two ongoing trials with BXCL701 in aggressive forms of prostate cancer and advanced solid tumors are expected in mid-2021

Windom women face drug charges

BioXcel Therapeutics Provides Update on its BXCL501 Program for the Acute Treatment of Dementia Related Agitation

BioXcel Therapeutics Provides Update on its BXCL501 Program for the Acute Treatment of Dementia Related Agitation March 03, 2021 07:00 ET | Source: BioXcel Therapeutics BioXcel Therapeutics Review of TRANQUILITY data show ed 30 mcg dose met statistical significance across multiple scales Company initiated supplemental 40 mcg dose cohort to help inform clinical development strategy across the full range of dementia care settings End of Phase 2 meeting scheduled with U.S. Food and Drug Administration (“FDA”) in Q2 2021 Pivotal Phase 3 program expected to begin in the second half of 2021 NEW HAVEN, Conn., March 03, 2021 (GLOBE NEWSWIRE) BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced an update to its BXCL501 dementia program, includi

BioXcel Therapeutics Appoints June Bray to Board of Directors

BioXcel Therapeutics Appoints June Bray to Board of Directors Former Allergan executive brings extensive global regulatory experience across multiple therapeutic areas March 01, 2021 07:00 ET | Source: BioXcel Therapeutics BioXcel Therapeutics New Haven, Connecticut, UNITED STATES NEW HAVEN, Conn., March 01, 2021 (GLOBE NEWSWIRE) BioXcel Therapeutics, Inc. ( BioXcel or the Company ) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the appointment of June Bray to its Board of Directors. Ms. Bray brings over forty years of extensive U.S. and global regulatory experience in the healthcare industry and most recently served as Senior Vice President, Global Regulatory Affairs and Medical Writing at Allergan.

Buena Vista Police Department reports arrests, citations

Buena Vista Police Department reports arrests, citations
chaffeecountytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from chaffeecountytimes.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.